Immune profiling in patients with recurrent miscarriage. (April 2015)

• Record Type: Journal Article
• Authors: Kuon, R.J.; Strowitzki, T.; Sohn, C.; Daniel, V.; Toth, B.
• Is Part Of: Journal of reproductive immunology. Volume 108(2015)
• Page Start: 136
• Page End: 141
• Publication Date: 2015-04
• Subjects: Recurrent miscarriage -- Immunological diagnosis -- NK cells -- Cytokines; Reproduction -- Immunological aspects -- Periodicals; Immunology -- Periodicals; Allergy and Immunology -- Periodicals; Reproduction -- Periodicals; Reproduction -- Immunologie -- Périodiques; Immunologie -- Périodiques; Immunology; Reproduction -- Immunological aspects; Periodicals; Electronic journals; Electronic journals; 615.766
• DOI: 10.1016/j.jri.2015.01.007
• Languages: English
• ISSNs: 0165-0378

Abstract

Highlights: There is evidence of immunological abnormalities in recurrent miscarriage patients. Only screening for antiphospholipid syndrome is recommended in all guidelines. Controlled trials are needed to provide a standardized immunological work-up. Diagnosis and immunological treatments should be concentrated in specialized centers. Abstract: The central role of the maternal immune system for successful and disturbed pregnancies such as recurrent miscarriage (RM) is apparent. Recent studies have increased understanding of the complex interaction of the different immunological players and the adaptation of the maternal immune system to the semi-allogeneic embryo. There is growing evidence for immunological abnormalities in RM patients, including autoimmune and allogeneic factors. However, the question remains unsolved whether these changes represent the cause or the consequence of RM. As in half of the RM patients the underlying mechanism remains unknown, further diagnostic methods are urgently needed. Within this review we summarize (recent) literature on the immunological diagnosis in RM patients to find out current trends and to identify potential targets of therapy. As the exact mechanisms of feto-maternal tolerance have not yet been determined we suggest that the immunological diagnosis should be implemented only in well-designed clinical trials in specialized centers to establish a standardized immunological work-up in RM patients.